Clinical activity of targeted antibodies, such as daratumumab (anti-CD38 antibody) and brentuximab vedotin (anti-CD30 antibody), have been reported in NKTCL. The gene discussed is TNFRSF8; the disease is extranodal nasal NK/T cell lymphoma.